newsbot.ch News https://www.newsbot.ch Die neusten Nachrichten auf newsbot.ch de-de Redaktion redaktion@content-provider.ch Tue, 11 Aug 2020 03:56:35 +0000 Daily News 31 / 07 / 2020 European Commission Daily news Brussels, 31 Jul 2020 EU-Vietnam trade agreement enters into force The EU-Vietnam trade agreement, the most comprehensive trade agreement the EU has concluded with a dev https://www.newsbot.ch/news/63882/Ausland/Daily-News-31---07---2020 https://www.newsbot.ch/news/63882/Ausland/Daily-News-31---07---2020 2020-07-31 14:25:01 International community renews commitment to multilateral efforts to address tax challenges from digitalisation of the economy The international community reaffirmed its commitment to reach a consensus-based long-term solution to the tax challenges arising from the digitalisation of the economy, and will continue working towa https://www.newsbot.ch/news/54608/Wirtschaft/International-community-renews-commitment-to-multilateral-efforts-to-address-tax-challenges-from-digitalisation-of-the-economy https://www.newsbot.ch/news/54608/Wirtschaft/International-community-renews-commitment-to-multilateral-efforts-to-address-tax-challenges-from-digitalisation-of-the-economy 2020-01-31 12:20:16 FDA approves Roche’s Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). https://www.newsbot.ch/news/45079/Wirtschaft/FDA-approves-Roche’s-Rozlytrek-entrectinib-for-people-with-ROS1-positive-metastatic-non-small-cell-lung-cancer-and-NTRK-gene-fusion-positive-solid-tumours https://www.newsbot.ch/news/45079/Wirtschaft/FDA-approves-Roche’s-Rozlytrek-entrectinib-for-people-with-ROS1-positive-metastatic-non-small-cell-lung-cancer-and-NTRK-gene-fusion-positive-solid-tumours 2019-08-16 16:40:40 Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress Roche today announced new data for Hemlibra® (emicizumab) across multiple pivotal studies in people with haemophilia A with and without factor VIII inhibitors at the International Society on Thrombos https://www.newsbot.ch/news/43434/Wirtschaft/Roche-presents-a-broad-range-of-data-for-Hemlibra-demonstrating-continued-benefits-for-people-with-haemophilia-A-at-the-ISTH-2019-Congress https://www.newsbot.ch/news/43434/Wirtschaft/Roche-presents-a-broad-range-of-data-for-Hemlibra-demonstrating-continued-benefits-for-people-with-haemophilia-A-at-the-ISTH-2019-Congress 2019-07-09 09:20:15 Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine Roche today announced results from the pivotal phase III CLL14 study in previously untreated chronic lymphocytic leukaemia (CLL) showing that Venclexta®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvar https://www.newsbot.ch/news/40726/Wirtschaft/Pivotal-phase-III-CLL14-results-for-Venclexta-Venclyxto-in-combination-with-Gazyva-Gazyvaro-for-chronic-lymphocytic-leukaemia-presented-at-ASCO-2019-and-published-in-the-New-England-Journal-of-Medicine https://www.newsbot.ch/news/40726/Wirtschaft/Pivotal-phase-III-CLL14-results-for-Venclexta-Venclyxto-in-combination-with-Gazyva-Gazyvaro-for-chronic-lymphocytic-leukaemia-presented-at-ASCO-2019-and-published-in-the-New-England-Journal-of-Medicine 2019-06-04 19:20:00 Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia Roche today announced that the US Food and Drug Administration (FDA) has approved Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) for the treatment of people with previously untreated https://www.newsbot.ch/news/39588/Wirtschaft/Roche-announces-FDA-approval-for-Venclexta-plus-Gazyva-for-people-with-previously-untreated-chronic-lymphocytic-leukaemia https://www.newsbot.ch/news/39588/Wirtschaft/Roche-announces-FDA-approval-for-Venclexta-plus-Gazyva-for-people-with-previously-untreated-chronic-lymphocytic-leukaemia 2019-05-16 08:40:14 FDA approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) t https://www.newsbot.ch/news/36127/Wirtschaft/FDA-approves-Roche’s-Tecentriq-in-combination-with-chemotherapy-for-the-initial-treatment-of-adults-with-extensive-stage-small-cell-lung-cancer https://www.newsbot.ch/news/36127/Wirtschaft/FDA-approves-Roche’s-Tecentriq-in-combination-with-chemotherapy-for-the-initial-treatment-of-adults-with-extensive-stage-small-cell-lung-cancer 2019-03-19 07:20:00 Roche joins the World Federation of Hemophilia Humanitarian Aid Program Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Hemlibra®(emicizumab) for routine prophylaxi https://www.newsbot.ch/news/33962/Wirtschaft/CHMP-recommends-EU-approval-of-Roches-Hemlibra-for-people-with-severe-haemophilia-A-without-factor-VIII-inhibitors https://www.newsbot.ch/news/33962/Wirtschaft/CHMP-recommends-EU-approval-of-Roches-Hemlibra-for-people-with-severe-haemophilia-A-without-factor-VIII-inhibitors 2019-02-06 09:20:00